Methylphenidate Hydrochloride Tablet, Extended Release
Product Images NDC 51407-927

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 51407-927). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-924-01 (pl).jpg (51407 924 01 (pl))

51407-924-01 (pl).jpg (51407 924 01 (pl))
Label for Methylphenidate Hydrochloride extended-release tablets, 18 mg strength. The label includes drug name, strength in a blue box, dosage form as tablets, and instructions to dispense the medication guide. It states 100 tablets per container and Rx only status. Marketed by GSMS, Incorporated, with storage and safety instructions also visible.*
FDA Label Image

51407-925-01 (pl).jpg (51407 925 01 (pl))

51407-925-01 (pl).jpg (51407 925 01 (pl))
Label for Methylphenidate Hydrochloride Extended-Release Tablets USP, 27 mg strength, marketed by GSMS, Incorporated. The label includes storage instructions, dosage note, a barcode, and states a package quantity of 100 tablets, Rx only. The label emphasizes keeping medication out of children’s reach and dispensing medication guides to patients.*
FDA Label Image

51407-926-01 (pl).jpg (51407 926 01 (pl))

51407-926-01 (pl).jpg (51407 926 01 (pl))
Label for Methylphenidate Hydrochloride extended-release tablets, USP, 36 mg strength. The label includes storage instructions, prescribing information notice, and safety warning to keep medication out of reach of children. Marketed by GSMS, Incorporated. Packaging contains 100 tablets and is Rx only. The label also displays the NDC 51407-926-01 and a barcode.*
FDA Label Image

51407-927-01 (pl).jpg (51407 927 01 (pl))

51407-927-01 (pl).jpg (51407 927 01 (pl))
Methylphenidate Hydrochloride 54 mg Extended-Release Tablets label showing product strength, extended-release form, and package size of 100 tablets. The label includes storage instructions, a barcode, and the marketer identified as GSMS, Incorporated, Camarillo, CA. It is a prescription drug with a warning to keep medication out of children's reach.*
FDA Label Image

Structural Formula (Methylphenidate Hydrochloride Extended Release Tab 1)

Structural Formula (Methylphenidate Hydrochloride Extended Release Tab 1)
Chemical structure of methylphenidate hydrochloride, showing the molecular arrangement of atoms including a phenyl ring, ester functional group, and the hydrochloride salt form.*
FDA Label Image

Figure 1 (Methylphenidate Hydrochloride Extended Release Tab 2)

Figure 1 (Methylphenidate Hydrochloride Extended Release Tab 2)
A line graph comparing the mean plasma methylphenidate concentration (ng/mL) over time (hours) for two dosing regimens: Methylphenidate HCl Extended-Release Tablets 18 mg once daily and Methylphenidate 5 mg three times daily. The graph shows concentration levels on the y-axis and time on the x-axis, illustrating the pharmacokinetic profiles of the two formulations over a 32-hour period.*
FDA Label Image

Figure 2 (Methylphenidate Hydrochloride Extended Release Tab 3)

Figure 2 (Methylphenidate Hydrochloride Extended Release Tab 3)
A bar chart comparing maximum symptoms on the Inattention/Overactivity Scale between methylphenidate hydrochloride extended-release tablets once daily and placebo across three studies. Each study shows two bars: a black bar for methylphenidate and a white bar for placebo, with placebo consistently higher, indicating more symptoms.*
FDA Label Image

Figure 3 (Methylphenidate Hydrochloride Extended Release Tab 4)

Figure 3 (Methylphenidate Hydrochloride Extended Release Tab 4)
A line graph comparing combined attention subscale scores over 12 hours after an initial dose between methylphenidate hydrochloride extended-release tablets and placebo. The y-axis measures attention from less attentive to more attentive, and the x-axis shows hours post initial dose. Data points include mean values with standard error bars, illustrating differences between drug and placebo groups over time.*
FDA Label Image

Tirgen Logo (Methylphenidate Hydrochloride Extended Release Tab 5)

FDA Label Image

Trigen Logo (Methylphenidate Hydrochloride Extended Release Tab 6)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.